Population-level adult mortality following the expansion of antiretroviral therapy in Rakai, Uganda.

DoreanNabukalu; Georges Reniers ORCID logo; Kathryn A Risher ORCID logo; SylviaBlom; Emma Slaymaker ORCID logo; ChodziwadziwaKabudula; Basia Zaba ORCID logo; FredNalugoda; GodfreyKigozi; FredMakumbi; +8 more... DavidSerwadda; Steven JReynolds; Milly Marston ORCID logo; Jeffrey WEaton; RonGray; MariaWawer; NelsonSewankambo; TomLutalo; (2019) Population-level adult mortality following the expansion of antiretroviral therapy in Rakai, Uganda. Population Studies, 74 (1). pp. 93-102. ISSN 0032-4728 DOI: 10.1080/00324728.2019.1595099
Copy

There are limited data on the impact of antiretroviral therapy (ART) on population-level adult mortality in sub-Saharan Africa. We analysed data for 2000-14 from the Rakai Community Cohort Study (RCCS) in Uganda, where free ART was scaled up after 2004. Using non-parametric and parametric (Weibull) survival analysis, we estimated trends in average person-years lived between exact ages 15 and 50, per capita life-years lost to HIV, and the mortality hazards of people living with HIV (PLHIV). Between 2000 and 2014, average adult life-years lived before age 50 increased significantly, from 26.4 to 33.5 years for all women and from 28.6 to 33.8 years for all men. As of 2014, life-years lost to HIV had declined significantly, to 1.3 years among women and 0.4 years among men. Following the roll-out of ART, mortality reductions among PLHIV were initially larger in women than men, but this is no longer the case.



picture_as_pdf
Population level adult mortality following the expansion of antiretroviral therapy in Rakai Uganda.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download

Explore Further

Read more research from the creator(s):

Find work associated with the faculties and division(s):

Find work associated with the research centre(s):

Find work from this publication: